New drug tested in patients with liver disease – safety first

NCT ID NCT06812780

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how the drug AZD2389 behaves in people with liver impairment compared to healthy volunteers. 35 adults took a single dose, and researchers measured drug levels in the blood to check safety and processing. The goal is to understand if liver problems change how the drug works, which helps guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD2389
What this could lead to: If successful, this study could help doctors determine the right dose of AZD2389 for patients with liver disease, making the drug safer to use.
What could go wrong: This is an early-stage study with only 35 participants. It focuses on how the body handles the drug, not on treating a disease, so it may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver follicular lymphoma liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Research Site

Chandler, Arizona, 85225, United States
Research Site

Rialto, California, 92377, United States
Research Site

Miami Lakes, Florida, 33014, United States
Research Site

Orlando, Florida, 32809, United States
Research Site

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.